The Connectivity Map: a new tool for biomedical research
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The ultimate objective of biomedical research is to connect human diseases with the genes that underlie them and drugs that treat them. But this remains a daunting task, and even the most inspired researchers still have to resort to laborious screens of genetic or chemical libraries. What if at least some parts of this screening process could be systematized and centralized? And hits found and hypotheses generated with something resembling an internet search engine? These are the questions the Connectivity Map project set out to answer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they do not support complex molecular readouts such as transcriptome profiling, which is one of the most comprehensive and informative measures of cellular response 5 .”
From Pooled CRISPR screening with single-cell transcriptome readout. (2017) · cites this paper as [5]
In the citing paper
“This tool allowed researchers to investigate genome-wide effects of GHK and establish that GHK-Cu is able to up- and down-regulate a significant number of human genes.”
From Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (2018) · cites this paper as [3]
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Self-citationDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“) to rationality (chronic myeloid leukaemia–BCR-ABL–imatini”
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Cited by
Items 301–400 of 984
Understanding drugs and diseases by systems biology?
Schneider, H.-C., & Klabunde, T. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.031 · Cited by 36
Large-Scale Elucidation of Drug Response Pathways in Humans
Silberberg, Y., Gottlieb, A., Kupiec, M., Ruppin, E., & Sharan, R. (2012) · Journal of Computational Biology · doi:10.1089/cmb.2011.0264 · Cited by 31
“Chen et al. (2010) proposed an algorithm for extracting drug response-enriched sub-pathways from KEGG pathways, exploiting drug-specific gene expression data from the Connectivity Map (CMap) (Lamb, 2007).”
Karatzas, E., Bourdakou, M. M., Kolios, G. C., & Spyrou, G. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12849-8 · Cited by 33
Exploring Drug Treatment Patterns Based on the Action of Drug and Multilayer Network Model
Yu, L., Shi, Y., Zou, Q., Wang, S., Zheng, L., & Gao, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145014 · Cited by 30
Smith, P. A., Merritt, D., Barr, L., & Thorley‐Lawson, D. A. (2011) · Genes & Cancer · doi:10.1177/1947601912440878 · Cited by 30
Williams, V. R., Konvalinka, A., Song, X., Zhou, X., John, R., Pei, Y., & Scholey, J. W. (2020) · Kidney International · doi:10.1016/j.kint.2020.01.029 · Cited by 34
In silico drug discovery: a machine learning-driven systematic review
Atasever, S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03260-w · Cited by 33
Integrative Genomics Strategies to Elucidate the Complexity of Drug Response
Kasarskis, A., Yang, X., & Schadt, E. E. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.115 · Cited by 30
Guzmán, E. A., Xu, Q., Pitts, T. P., Mitsuhashi, K. O., Baker, C. H., Linley, P. A., Oestreicher, J., TenDyke, K., Winder, P. L., Suh, E. M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30253 · Cited by 29
“The gene expression pattern was analyzed using the Broad Institute Connectivity Map Resource that matches the effects of small molecules on gene expression with known compounds that share a similar mechanism of action.(20,21) The connectivity map showed that leiodermatolide matched to four known tubulin interacting co…”
MethodThe Neuroimmune Transcriptome and Alcohol Dependence: Potential for Targeted Therapies
Warden, A. S., Erickson, E. K., Robinson, G., Harris, R. A., & Mayfield, R. D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0062 · Cited by 31
Hosomi, K., Fujimoto, M., Ushio, K., Mao, L., Kato, J., & Takada, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204648 · Cited by 33
Al-Taie, Z., Liu, D., Mitchem, J. B., Papageorgiou, C., Kaifi, J. T., Warren, W. C., & Shyu, C. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103792 · Cited by 32
Drug repurposing in silico screening platforms
Mullins, J. G. L. (2022) · Biochemical Society Transactions · doi:10.1042/bst20200967 · Cited by 34
Translational Bioinformatics Approaches to Drug Development
Readhead, B., & Dudley, J. T. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0422 · Cited by 31
“We extracted the 100 most differentially expressed genes, which comprised 25 upregulated (Table 1) and 75 downregulated genes (Table 2), which we used as the basis of a query signature, for use with Connectivity Map.37,38 We present the top 16 compounds (Table 3) which were found to have an ‘‘opposite’’ transcriptiona…”
MethodMoving Forward in Human Cancer Risk Assessment
Paules, R. S., Aubrecht, J., Corvi, R., Garthoff, B., & Kleinjans, J. C. S. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002735 · Cited by 32
“Further progress must be made in systems toxicology applications, 742 volume 119 | number 6 | June 2011 • Environmental Health Perspectives that is, developing integrative approaches across multiple genomic, genetic, molecu lar, and cellular assays to assess toxic events from a holistic perspective, as described with…”
BackgroundInfluentialWen, Q., O’Reilly, P. G., Dunne, P. D., Lawler, M., Schaeybroeck, S. V., Salto‐Tellez, M., Hamilton, P., & Zhang, S. (2015) · BMC Systems Biology · doi:10.1186/1752-0509-9-s5-s4 · Cited by 28
“The reference database of the Broad Institute Connectivity Map 02 contains 6100 individual reference profiles for 1309 small molecule compounds, many of which were FDA approved drugs [6].”
BackgroundGao, L., Zhao, G., Fang, J., Yuan, T., Liu, A., & Du, G. (2014) · FEBS Journal · doi:10.1111/febs.12672 · Cited by 30
“Connectivity Map (CMap) [4] is a computational drug repositioning tool.”
MethodConnectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma
Beck, A., Eberherr, C., Hagemann, M., Cairo, S., Häberle, B., Vokuhl, C., von Schweinitz, D., & Kappler, R. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235664 · Cited by 28
“tion of potential new treatment options utilizing biomedical software called the Connectivity Map (CMap).(10,11) CMap is”
MethodBelizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 29
“The Connectivity Map 12 uses the concept of connectivity based on compound-gene signature developed by Todd Golub’s group at Broad Institute of MIT, Whitehead Institute and Harvard Medical School, Massachusetts (Lamb et al., 2006; Lamb, 2007).”
BackgroundMethodKondo, T. (2021) · Cancer Science · doi:10.1111/cas.14669 · Cited by 30
Faria, C. C., Agnihotri, S., Mack, S. C., Golbourn, B. J., Diaz, R. J., Olsen, S., Bryant, M., Bebenek, M., Wang, X., Bertrand, K. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4304 · Cited by 28
“The C-MAP contains gene expression signatures of various cultured cancer cell lines treated with a library of small molecule compounds already approved by the Food and Drug Administration (FDA) [7, 8].”
BackgroundRavindranath, A. C., Perualila, N. J., Kasim, A., Drakakis, G., Liggi, S., Brewerton, S. C., Mason, D. J., Bodkin, M. J., Evans, D. A. P., Bhagwat, A. M., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00328d · Cited by 31
Hung, Y.-H., Huang, H.-L., Chen, W.-C., Yen, M., Cho, C.-Y., Weng, T., Wang, C., Chen, Y., Chen, L., & Lai, M.-D. (2016) · Oncology Reports · doi:10.3892/or.2016.5334 · Cited by 28
“org/cmap/) (32,33) was applied with default setting.”
MethodMaster Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug Repositioning
Bastiani, M. A. D., Pfaffenseller, B., & Klamt, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00697 · Cited by 30
“Hence, they proposed the need to switch the entire state of the system to a more favorable one, through modulation of many targets simultaneously (Lamb, 2007).”
BackgroundTargeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells
Xu, X., Huang, L., Zhang, Z., Tong, J., Mi, J., Wu, Y., Zhang, C.-L., & Yan, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.034 · Cited by 28
Aramadhaka, L. R., Prorock, A. J., Dragulev, B. P., Bao, Y., & Fox, J. W. (2013) · Toxicon · doi:10.1016/j.toxicon.2013.03.018 · Cited by 30
“In 2006, Lamb and colleagues published an approach that utilized both experimental and computational methods to undertake a systematic approach to illuminate the functional association between diseases, genetic perturbations and drug action (Lamb et al., 2006; Lamb, 2007).”
BackgroundcudaMap: a GPU accelerated program for gene expression connectivity mapping
McArt, D. G., Bankhead, P., Dunne, P. D., Salto‐Tellez, M., Hamilton, P., & Zhang, S. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-305 · Cited by 27
“Using a common “vocabulary” of gene expression profiling [2], connectivity mapping allows the establishment/discovery of connections between different biological states via their gene expression patterns or characteristics, with great potential for application in areas like predictive toxicity [3], candidate therapeut…”
BackgroundComputational Functional Genomics-Based Approaches in Analgesic Drug Discovery and Repurposing
Lippmann, C., Kringel, D., Ultsch, A., & Lötsch, J. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0036 · Cited by 33
Xu, X., Khunsriraksakul, C., Eales, J., Rubin, S., Scannali, D., Saluja, S., Talavera, D., Markus, H., Wang, L., Drzal, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46132-y · Cited by 32
“Tocharacterisekidney speci fi city, we retrieved miRNA expression data for multiple tissues from miRNATissueAtlas2 52 .”
InfluentialTate, T. A., Wambaugh, J. F., Patlewicz, G. Y., & Shah, I. (2021) · Computational Toxicology · doi:10.1016/j.comtox.2021.100171 · Cited by 26
Masson, S. W. C., Madsen, S., Cooke, K. C., Potter, M., Díaz‐Vegas, A., Carroll, L., Thillainadesan, S., Cutler, H. B., Walder, K. R., Cooney, G. J., et al. (2023) · eLife · doi:10.7554/elife.86961 · Cited by 24
Marstrand, T. T., Borup, R., Willer, A., Borregaard, N., Sandelin, A., Porse, B. T., & Theilgaard‐Mönch, K. (2010) · Leukemia · doi:10.1038/leu.2010.95 · Cited by 28
Caberlotto, L., & Lauria, M. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.975214 · Cited by 27
“This later approach has been applied by Lamb [57] , which created gene expression signatures from treatment of FDA-approved drugs on human cell lines in vitro indicating that structurally different compounds that converge on common targets can yield the same gene expression signature.”
MethodThe prognostic significance of DAPK1 in bladder cancer
Xie, J.-Y., Chen, P.-C., Zhang, J., Gao, Z., Neves, H., Zhang, S., Wen, Q., Chen, W., Kwok, H. F., & Lin, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175290 · Cited by 26
Tian, S., Liao, X., Cao, W., Wu, X., Chen, Z., Lu, J., Wang, Q., Zhang, J., Chen, L., & Zhang, W. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.017 · Cited by 27
“Additionally, various computational algorithms leveraging gene expression data have been developed to support drug discovery 10-13 .”
Alishvandi, A., Barancheshemeh, M., Firuzpour, F., Aram, C., Kamali, M. J., & Keikha, M. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107691 · Cited by 29
Cell line modeling for systems medicine in cancers (Review)
KIM, N., He, N., & Yoon, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2202 · Cited by 27
Su, C., Tseng, C.-L., Ramesh, C., Liu, H., Huang, C. F., & Yao, C. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.034 · Cited by 26
Liu, H., Zhou, Q., Wei, W., Qi, B., Zeng, F., Bao, N., Li, Q., Guo, F., & Xia, S. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00309-x · Cited by 26
Liu, L.-W., Hsieh, Y., & Yang, P. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030130 · Cited by 33
“It is believed that a drug has the potential for treating a disease if this drug could reverse the disease-associated gene signature [39,40].”
BackgroundOu, O. L., Huppi, K. E., Chakka, S., Gehlhaus, K., Dubois, W., Patel, J. D., Chen, J., Mackiewicz, M., Jones, T. L., Pitt, J. J., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.043 · Cited by 25
“As specific inhibitors of most of the rapamycin-sensitizers identified by RNAi are unavailable we sought an alternative approach to their pharmacological inhibition by conducting an analysis of the Connectivity Map dataset of compound-associated gene expression available for MCF7 cells [23].”
BackgroundTargeted therapy in gastric cancer: Personalizing cancer treatment based on patient genome
Lim, S. M., Lim, J. Y., & Cho, J. Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.2042 · Cited by 30
Gillet, J., Andersen, J. B., Madigan, J. P., Varma, S., Bagni, R., Powell, K., Burgan, W. E., Wu, C., Calcagno, A. M., Ambudkar, S. V., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.101360 · Cited by 28
“Another approach highlighted in this work is to use a resource published earlier by the Golub group, the Connectivity Map, which allows the identification of compounds that might sensitize MDR cancers with a specific gene signature (Lamb et al., 2006; Lamb, 2007; Zhang and Gant, 2008).”
BackgroundMethodSiwo, G., Smith, R. S., Tan, A., Button-Simons, K. A., Checkley, L. A., & Ferdig, M. T. (2015) · BMC Genomics · doi:10.1186/s12864-015-2165-1 · Cited by 26
“For instance, the Connectivity Map (CMap) [8, 9], a database of gene expression profiles from cancer cell lines exposed to multiple drugs of known MOA has been used to successfully predict the MOA of new drugs [10, 11].”
MethodWu, Y., Yeh, I., Phan, N. N., Yen, M., Hung, J., Chiao, C.-C., Chen, C., Sun, Z., Hsu, H., Wang, C., et al. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.03.007 · Cited by 33
“The miRNA-targeted genes from MERS-CoV-infected cells were compared to those from mock-infected controls through the CMap platform.(24,25) CMap applies a systematic approach to reveal interactions among diseases and to reveal FDA-approved compounds, based on alterations in the gene expressions of MERS-CoV-infected cel…”
MethodApplications of In Silico Models to Predict Drug-Induced Liver Injury
Lin, J., Li, M., Mak, W. Y., Shi, Y., Zhu, X., Tang, Z., He, Q., & Xiang, X. (2022) · Toxics · doi:10.3390/toxics10120788 · Cited by 25
“Most gene expression data are accessible in some large-scale biomedical datasets such as the Connectivity Map (CMap) project, which is a collection of transcriptional expression data derived from cultured human cells treated with various compounds [70] and Genomics-Assisted Toxicity Evaluation System (TG-GATEs), anoth…”
Gant, T. W., Auerbach, S. S., von Bergen�, M., Bouhifd, M., Botham, P. A., Caiment, F., Currie, R. A., Harrill, J., Johnson, K. J., Li, D., et al. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03522-3 · Cited by 26
“The connectivity mapping approach was raised as a way forward of dealing with this question (Lamb 2007; Lamb et al. 2006; Zhang and Gant 2009).”
MethodCancer Biology, Toxicology and Alternative Methods Development Go Hand‐in‐Hand
Kohonen, P. J., Ceder, R., Smit, I. A., Hongisto, V., Myatt, G. J., Hardy, B. J., Spjuth, O., & Grafström, R. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12257 · Cited by 28
Systems Biology: An Evolving Approach in Drug Discovery and Development
Ho, R. L., & Lieu, C. A. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00001 · Cited by 25
Sirci, F., Napolitano, F., Pisonero‐Vaquero, S., Carrella, D., Medina, D. L., & di Bernardo, D. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0022-3 · Cited by 27
“6 The Connectivity Map (CMAP), the largest peer-reviewed public database of gene expression pro fi les following treatment of fi ve human cancer cell lines with 1309 different bioactive small molecules, 2, 7 has been extensively used by both the academic and industrial communities.”
MethodInfluentialWen, Y.-L., Zhang, Y., Li, J., Luo, F., Huang, Z., & Liu, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-19413-y · Cited by 24
Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
Machado, S., da Silva, A. M., Sousa‐Coelho, A. L. D., Duarte, I., Grenho, I., Santos, B., Mayoral-Varo, V., Megías, D., Sánchez‐Cabo, F., Dopazo, A., et al. (2020) · Cancers · doi:10.3390/cancers12123689 · Cited by 26
“The enrichment scores were calculated based on the Kolmogorov–Smirnov statistic, a non-parametric rank statistic, also known as gene set enrichment analysis (GSEA), to interpret gene expression data [38,39]”
MethodCovell, D. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127433 · Cited by 25
“‘Signature’ genes are commonly used to assess whether a subset of gene expressions are sufficiently comparable to indicate a likelihood of a similar biological condition or therapeutic response [17,18].”
BackgroundCovell, D. G., Wallqvist, A., Kenney, S., & Vistica, D. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048023 · Cited by 24
Sudo, M., Mori, S., Madan, V., Yang, H. H., Leong, G., & Koeffler, H. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2891 · Cited by 25
“The Connectivity Map is a genomic screening tool for linking genes associated with a selected phenotype with potential therapeutic agents [31, 32].”
MethodDiverse approaches to predicting drug-induced liver injury using gene-expression profiles
Sumsion, G. R., Bradshaw, M. S., Beales, J. T., Ford, E., Caryotakis, G. R. G., Garrett, D. J., LeBaron, E. D., Nwosu, I. O., & Piccolo, S. (2020) · Biology Direct · doi:10.1186/s13062-019-0257-6 · Cited by 24
Qiang, W., Dai, Y., Xing, X., & Sun, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.046 · Cited by 24
“Connectivity Map (CMap, https://portals.broadinstitute.org/ cmap/) is an online analysis platform based on genome-wide transcriptional expression data for the study on the mechanism of action and repurposing of small molecules [24,25].”
Chong, L. C., Gandhi, G., Lee, J. M., Yeo, W. W. Y., & Choi, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168962 · Cited by 26
Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform
Guedj, M., Swindle, J., Hamon, A., Hubert, S., Desvaux, E., Laplume, J., Xuereb, L., Lefèbvre, C., Haudry, Y., Gabarroca, C., et al. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2095368 · Cited by 32
“The knowledge graph used in Patrimony has thus also been applied to such drug repurposing approaches, by using both distances between drug targets and disease-related proteins [69], connectivity maps [23,24], and deep-learning methodol-”
MethodEIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer
Li, K., Tan, G., Zhang, X., Lu, W., Ren, J., Si, Y., Adu‐Gyamfi, E. A., Li, F., Wang, Y., Xie, B., et al. (2022) · Biomolecules · doi:10.3390/biom12121756 · Cited by 22
“io/, accessed on 10 August 2022), a novel database used to study gene interactions and drugs, can be applied for discovering potentially effective molecules against certain diseases [40].”
BackgroundTranscriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data
Wolf, H. D., Bondt, A. D., Turner, H., & Göhlmann, H. W. H. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.715 · Cited by 23
“grounds, which are likely to reveal different biological effects, (3) compound concentrations, with low concentrations likely to expose highly potent interactions between a small molecule and its respective target and high concentrations tending to show less specific or even toxic effects, and (4) time points,”
BackgroundMethodXie, H., Wen, H., Qin, M., Xia, J., Zhang, D., Liu, L., Лю, Б., Liu, Q., Jin, Q., & Chen, X. (2016) · RSC Advances · doi:10.1039/c6ra21941a · Cited by 24
Molecular Network-Based Drug Prediction in Thyroid Cancer
Xu, X., Long, H., Xi, B., Ji, B., Li, Z., Dang, Y., Jiang, C., Yao, Y., & Yang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020263 · Cited by 23
“Recently, more and more successful applications of CMAP have been reported, such as the study of nematodes to identify compounds that mimic caloric restriction [6–8].”
BackgroundMethodInfluentialSousa, M. L., Preto, M., Vasconcelos, V. M., Linder, S. T., & Urbatzka, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00224 · Cited by 23
“The transcriptome profile was determined after 6 h exposure of MCF7 cells to 7μM NocA and signatures with connectivity score (τ ) higher than 90 were selected (35, 36, 44).”
MethodLeung, S. W., Chou, C.-J., Huang, T., & Yang, P. (2019) · Cancers · doi:10.3390/cancers11101482 · Cited by 23
“It is believed that, if the queried gene signature for a specific disease can be reversed in small-molecule-treated or gene-knockdown/overexpressing cells, the corresponding small molecules or genes (either knockdown or overexpression) might have therapeutic or suppressive effect against this disease [35,36].”
BackgroundMaking sense of OMICS data in population‐based environmental health studies
Kyrtopoulos, S. Α. (2013) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21778 · Cited by 23
“…or toxicity prediction [Audouze et al., 2010; Szklarczyk et al., 2011; Kanehisa et al., 2012; Kamburov et al., 2013], while databases such as the Comparative Toxicogenomics Database [Davis et al., 2013], the Disease Connectivity database [Lamb, 2007] and others can also be of great value.”
BackgroundZhang, Z., Meng, T., He, J., Li, M., Tong, L., Xiong, B., Lin, L., Shen, J., Miao, Z., & Ding, J. H. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9303-z · Cited by 23
“Connectivity Map is a novel method based on the hypothesis that drugs sharing similar mechanisms result in similar changes in the gene expression profiles [14, 15 ].”
BackgroundMethodInfluentialQi, R., Liu, S., Hui, X., Shaytan, A. К., & Liu, B. (2025) · Science China Information Sciences · doi:10.1007/s11432-024-4461-0 · Cited by 29
“Drug databases like DrugBank and CMap offer pharmacological insights, which, combined with clinical data, enable predictive models of drug efficacy and safety [60].”
ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma
Liu, Z., Lian, X., Zhang, X., Zhu, Y., Zhang, W., Wang, J., Wang, H., Liu, B., Ren, Z., Zhang, M., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.666106 · Cited by 22
“Connectivity Map (CMap) is a drug research and development system founded by Harvard University and is a common tool for discovering the potential therapeutic effects of drugs (Lamb, 2007).”
MethodInhibition of rotavirus infection in cultured cells by N-acetyl-cysteine, PPARγ agonists and NSAIDs
Guererero, C. A., Murillo, A., & Acosta, O. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.06.011 · Cited by 22
Computational Drug Repositioning Using Continuous Self-Controlled Case Series
Kuang, Z., Thomson, J., Caldwell, M. D., Peissig, P. L., Stewart, R. M., & Page, D. (2016) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/2939672.2939715 · Cited by 25
“Many methods leverage genotypic and transcriptomic information [4, 5], as well as drug molecular structure and drug combination information [6, 7].”
MethodHuman enterovirus 71 protein interaction network prompts antiviral drug repositioning
Han, L., Li, K., Jin, C., Wang, J., Li, Q., Zhang, Q., Cheng, Q., Yang, J., Bo, X., & Wang, S. (2017) · Scientific Reports · doi:10.1038/srep43143 · Cited by 22
“The connectivity map 21, 22 and Gene Set Enrichment Analysis (GSEA) 23 provided an applicable strategy for the evaluation of drug influences on a group of targets (i.e., signatures through expression profiles).”
MethodA Transcriptome‐Based Drug Discovery Paradigm for Neurodevelopmental Disorders
Dhindsa, R. S., Zoghbi, A. W., Krizay, D. K., Vasavda, C., & Goldstein, D. B. (2020) · Annals of Neurology · doi:10.1002/ana.25950 · Cited by 23
Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Gomez-Monterrey, I. M., Sala, M., Musella, S., & Campiglia, P. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212801820066 · Cited by 23
Systematizing Serendipity for Cardiovascular Drug Discovery
Schlueter, P. J., & Peterson, R. T. (2009) · Circulation · doi:10.1161/circulationaha.108.824177 · Cited by 24
Application of transcriptomics in Chinese herbal medicine studies
Lo, H., Li, C., Huang, H., Lin, L., Hsiang, C., & Ho, T. (2012) · Journal of Traditional and Complementary Medicine · doi:10.1016/s2225-4110(16)30083-9 · Cited by 23
“Connectivity Map compares lists of differential expressed genes to a library of experiments evaluating the effects of small molecules and genetic events on gene expression (Lamb et al., 2006; Lamb, 2007).”
BackgroundHuang, C., Ciou, J.-S., Chen, S.-T., Kok, V. C., Chung, Y., Tsai, J. J. P., Kurubanjerdjit, N., Huang, C. F., & Ng, K. (2016) · PeerJ · doi:10.7717/peerj.2478 · Cited by 23
“We made use of the drug-gene interaction databases, Connectivity Map (cMap) (Lamb, 2007), to find potential drugs for the treatments of VSMC proliferation associated diseases.”
MethodExtended Multitarget Pharmacology of Anticancer Drugs
Shi, D., Khan, F., & Abagyan, R. A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00031 · Cited by 25
Du, Y., Li, K., Wang, X., Kaushik, A. C., Junaid, M., & Wei, D. (2019) · FEBS Journal · doi:10.1111/febs.15102 · Cited by 21
Sun, J., Zhao, J., Yang, Z., Zhou, Z., & Lu, P. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-81 · Cited by 24
“Another public database, Connectivity Map (CMap), is a large-scale collection of gene-expression signatures that aids in the discovery of small molecular compounds with potential use in the treatment of specific diseases (7,8).”
BackgroundOskotsky, T., Bhoja, A., Bunis, D. G., Le, B. L., Tang, A., Kosti, I., Li, C., Houshdaran, S., Sen, S., Vallvé-Juanico, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109388 · Cited by 25
“77 For endometriosis, differential gene expression signatures were generated as described using six different stratifications: unstratified (all samples), stratified by stage (stages I-II or stages III-IV), and stratified by phase (PE, ESE, or MSE).”
MethodWang, W., McDonald, M. C. L., Hariprasad, R., Hamilton, T., & Frank, D. A. (2024) · Cancers · doi:10.3390/cancers16071387 · Cited by 24
“identifying target , amounts of data on how a wide variety of chemical compounds alter gene expression in a variety of cell types [222].”
Backgroundp53 Family: Therapeutic Targets in Neuroblastoma
Wolter, J. K., Angelini, P., & Irwin, M. S. (2010) · Future Oncology · doi:10.2217/fon.09.176 · Cited by 24
FacPad: Bayesian sparse factor modeling for the inference of pathways responsive to drug treatment
Ma, H., & Zhao, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts502 · Cited by 21
Hongo, H., Kosaka, T., Suzuki, Y., & Oya, M. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00426-0 · Cited by 23
Hajjo, R., Momani, E., Sabbah, D. A., Baker, N., & Tropsha, A. (2023) · npj Vaccines · doi:10.1038/s41541-023-00719-6 · Cited by 22
Luo, F., Gu, J., Zhang, X., Chen, L., Cao, L., Li, N., Wang, Z., Xiao, W., & Xu, X. (2015) · Scientific Reports · doi:10.1038/srep10064 · Cited by 20
“In order to explore the possible mechanism of the ingredients of RDN, we classified the ingredient molecules into three parts according their degree in drug-target network: high degree (31-62), middle degree (11-30) and low degree (1-10).”
BackgroundA VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis
Yin, X., Wang, X., Shen, B., Jing, Y., Li, Q., Cai, M., Gu, Z., Yang, Q., Zhang, Z., Liu, J., et al. (2016) · Scientific Reports · doi:10.1038/srep31079 · Cited by 21
Mears, A. J., Schock, S., Hadwen, J., Putos, S., Dyment, D. A., Boycott, K. M., & MacKenzie, A. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0018-3 · Cited by 20
“Although the Connectivity Map employed 1300 compounds 9, 10 and the CREKB subtends ~ 450,000 causal relations (12), for purposes of tractability the de fi nition of a subset of compounds was needed.”
Methodde Anda‐Jáuregui, G., Guo, K., & Hur, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020386 · Cited by 20
“One of the largest publicly available GE-HTS efforts is that of the original Connectivity Map (CMap) [5] and its continuation as part of the Library of Integrated Network-Based Cellular Signals (LINCS) [6,7].”
BackgroundIdentification of nagilactone E as a protein synthesis inhibitor with anticancer activity
Zhang, L., Guo, J., Jiang, X.-M., Chen, X.-P., Wang, Y.-T., Li, A., Lin, L., Li, H., & Lu, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0332-7 · Cited by 20
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells
Sacramento, C. Q., Rodrigues, N. F., Dias, S. D. S. G., Temerozo, J. R., da Silva, A. D. P. D., da Silva, C. S., Blanco, C. F., Ferreira, A. C., Mattos, M., Soares, V. C., et al. (2022) · Viruses · doi:10.3390/v14020374 · Cited by 22
Edris, B., Fletcher, J. A., West, R. B., van de Rijn, M., & Beck, A. H. (2012) · Sarcoma · doi:10.1155/2012/805614 · Cited by 20
“profiles with the Connectivity Map (cmap), a reference collection of gene expression profiles from cultured human cell lines (breast cancer epithelial cell line MCF7, prostate cancer cells PC3, leukemia cells HL60, and melanoma cells SKMEL5) treated with a large and diverse library of small molecules [4, 5].”
A statistical framework for high-content phenotypic profiling using cellular feature distributions
Pearson, Y. E., Kremb, S., Butterfoss, G. L., Xie, X., Fahs, H., & Gunsalus, K. C. (2022) · Communications Biology · doi:10.1038/s42003-022-04343-3 · Cited by 19
Navigating Transcriptomic Connectivity Mapping Workflows to Link Chemicals with Bioactivities
Shah, I., Bundy, J., Chambers, B., Everett, L. J., Haggard, D., Harrill, J., Judson, R. S., Nyffeler, J., & Patlewicz, G. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00245 · Cited by 19
A comparative chemogenic analysis for predicting Drug-Target Pair via Machine Learning Approaches
Kaushik, A. C., Mehmood, A., Dai, X., & Wei, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-63842-7 · Cited by 19
Bunyavanich, S., Becker, P. M., Altman, M. C., Lasky-Su, J. A., Ober, C., Zengler, K., Berdyshev, E. V., Bonneau, R., Chatila, T. A., Chatterjee, N., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.01.014 · Cited by 19
Mehmood, A., Kaushik, A. C., & Wei, D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01101 · Cited by 19
Flynn, C. R., Zheng, S., Yan, L., Hedges, L. K., Womack, B., Fessel, J. P., Cogan, J. D., Austin, E. D., Loyd, J. E., West, J. D., et al. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0251oc · Cited by 19
Drug-target interaction prediction for drug repurposing with probabilistic similarity logic
Fakhraei, S., Raschid, L., & Getoor, L. C. (2013) · doi:10.1145/2500863.2500870 · Cited by 25
“Expression-based: The Spearman rank correlation coefficient of gene expression responses to drugs retrieved from the Connectivity Map project [16, 17] was used as a similarity measure between drugs.”
Metadata
- Authors
- Lamb, J.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lamb, Justin
- Venue
- Nature Reviews Cancer
- Published
- 2007-01
- Volume
- 7
- Issue
- 1
- Pages
- 54-60
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2029980980
- Semantic Scholar
- d1610ee5045d33be16a9a72a514fea537ba46306
- Cited by
- 945
- References
- 66
- Citations by year
- 2026: 11 · 2025: 29 · 2024: 75 · 2023: 54 · 2022: 56 · 2021: 100 · 2020: 79 · 2019: 64 · 2018: 60 · 2017: 52 · 2016: 58 · 2015: 57 · 2014: 42 · 2013: 49 · 2012: 56
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Broad Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- Connectivity Map, gene-disease association, drug repurposing, gene expression profiling, cancer research, drug discovery
- MeSH terms
- Algorithms, Animals, Gene Expression Regulation, Humans, Information Services, Models, Biological, Models, Genetic, Neoplasms, Phenotype, Software, Information Storage and Retrieval, Genome, Computational Biology, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.